Welcome to the 500th Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the past seven days.
The first newsletter was sent on December 14th, 2011, and now nine and a half years later, we reach number 500. The entire archive of newsletters is safely stored and will be added to this latest version of the website as soon as I can do so. Newsletter 1 contained links to just 11 articles. The newsletter has grown to become the best resource for staying up-to-date with the critical care literature and is received by thousands globally every week. Like everything else at Critical Care Reviews, this is provided free of charge. We strive to promote open access to scientific advancement for the benefit of all, and do so across our range of activities - newsletter, website, meeting, livestreams, podcast and book. If you haven't yet helped support our work, please consider doing so. Our work is free to access, but neither free to create nor share.
The highlights of this week's edition are the WHO REACT Group's prospective systematic review and meta analysis on IL-6 antagonists in patients hospitalized for COVID-19; a small randomised controlled trial investigating induced hypernatremia in patients with moderate-to-severe ARDS; and an observational study on the effects of standard vs energy-dense formulae on gastric retention, energy delivery, and glycemia in critically ill patients. There are also guidelines on myocarditis in children & emergency laparotomy enhanced recovery after surgery; narrative reviews on non-invasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure & energetic dysfunction in sepsis; editorials on the worrying aspects of COVID-19 experimental interventions & the need for a comprehensive international clinical epidemiology of ARDS; and commentaries on when an airway plateau pressure above 30 cmH2O could be acceptable in ARDS patients & potential COVID-19 endgame scenarios; as well as correspondence on Choosing Wisely for COVID-19.
If you only have time to read one review article this week, try this one on acute respiratory distress syndrome.
Earlier in the week, Prof Manu Shankar-Hari joined me on the podcast to discuss the WHO REACT Group's prospective systematic review and meta analysis on IL-6 antagonists in COVID-19. Next week, I hope to have the latest edition to our podcast series on the REMAP-CAP adaptive platform trial, as well as Niklas Nielsen's answers to the questions posted by viewers on the TTM2 trial results livestream.
We have now confirmed two further major trial result livestreams, which will take place in early August. More details next week.